| 1 |
Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(10): 585-595.
|
| 2 |
Orchard TR, Wordsworth BP, Jewell DP.Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history[J]. Gut, 1998, 42(3): 387-391.
|
| 3 |
Salvarani C, Vlachonikolis IG, van der Heijde DM, et al.Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients[J]. Scand J Gastroenterol, 2001, 36(12): 1307-1313.
|
| 4 |
Peeters H, Vander Cruyssen B, Mielants H, et al.Clinical and genetic factors associated with sacroiliitis in Crohn′s disease[J]. J Gastroenterol Hepatol, 2008, 23(1): 132-137.
|
| 5 |
Puhakka KB, Jurik AG, Schi？ttz-Christensen B, et al.MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study[J]. Scand J Rheumatol, 2004, 33(5): 332-338.
|
| 6 |
Peluso R, Manguso F, Vitiello M, et al.Management of arthropathy in inflammatory bowel diseases[J]. Ther Adv Chronic Dis, 2015, 6(2): 65-77.
|
| 7 |
Braun J, Baraliakos X, Listing J, et al.Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response[J]. Ann Rheumat Dis, 2008, 67(3): 340-345.
|
| 8 |
Requena L, Sanchez Yus E. Erythema nodosum[J]. Semin Cutan Med Surg, 2007, 26(2): 114-125.
|
| 9 |
Andrisani G, Guidi L, Papa A, et al.Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease[J]. Eur Rev Med Pharmacol Sci, 2012, 16(7): 890-901.
|
| 10 |
Ruocco E, Sangiuliano S, Gravina AG, et al.Pyoderma gangrenosum: an updated review[J]. J Eur Acad Dermatol Venereol, 2009, 23(9): 1008-1017.
|
| 11 |
Lakatos PL, Lakatos L, Kiss LS, et al.Treatment of extraintestinal manifestations in inflammatory bowel disease[J]. Digestion, 2012, 86 Suppl 1: 28-35.
|
| 12 |
Ljung T, Staun M, Grove O, et al.Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab[J]. Scand J Gastroenterol, 2002, 37(9): 1108-1110.
|
| 13 |
Reinshagen M. Osteoporosis in inflammatory bowel disease[J]. J Crohns Colitis, 2008, 2(3): 202-207.
|
| 14 |
Bischoff-Ferrari HA, Willett WC, Wong JB, et al.Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials[J]. JAMA, 2005, 293(18): 2257-2264.
|
| 15 |
Soo I, Siffledeen J, Siminoski K, et al.Risedronate improves bone mineral density in Crohn′s disease: a two year randomized controlled clinical trial[J]. J Crohns Colitis, 2012, 6(7): 777-786.
|
| 16 |
Eaton JE, Talwalkar JA, Lazaridis KN, et al.Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management[J]. Gastroenterology, 2013, 145(3): 521-536.
|
| 17 |
Braden B, Halliday J, Aryasingha S, et al.Risk for colorectal neoplasia in patients with colonic Crohn′s disease and concomitant primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2012, 10(3): 303-308.
|
| 18 |
Lindor KD, Kowdley KV, Luketic VA, et al.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J]. Hepatology, 2009, 50(3): 808-814.
|
| 19 |
Higgins PD, Skup M, Mulani PM, et al.Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2015, 13(2): 316-321.
|
| 20 |
Chong LY, Fenu E, Stansby G, et al.Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance[J]. BMJ, 2012, 344: e3979.
|